Just Published: UTE T2* mapping of tendinopathic patellar tendons

Just Published: UTE T2* mapping of tendinopathic patellar tendons

UTE T2* mapping of tendinopathic patellar tendons: an MRI reproducibility study

There is currently a lack of imaging modalities that can be used as a sensitive measure in tendinopathy.

Tendinopathy, also called tendinosis, refers to the breakdown of collagen in a tendon. This causes burning pain in addition to reduced flexibility and range of motion. While tendinopathy can affect any tendon, it’s more common in the: Achilles tendon. rotator cuff tendons.

As newer imaging becomes available, it is important to assess its sensitivity and reproducibility of the measurements.

Recent findings suggest the applicability of ultra-short echo time (UTE) magnetic resonance imaging (MRI) T2* mapping in tendons.

These data demonstrate a small bias between repeated measurements for UTE T2*, but with a very low associated mean difference (3.7%) between the two tests.

The high ICC values and low typical error % demonstrate reproducibility of repeated T2*-mapping sessions.

The method showed substantial intra- and inter-observer reproducibility for T2* values proving feasibility for use of UTE T2* mapping in research and clinical practice.

Title: UTE T2* mapping of tendinopathic patellar tendons: an MRI reproducibility study.

Journal: Acta Radiologica 2021 Feb; 62(2):215-224

Authors: Anne-Sofie Agergaard, Nikolaj M Malmgaard-Clausen, Rene B Svensson, Janus D Nybing, Mikael Boesen, Michael Kjaer, S Peter Magnusson, Philip Hansen

Access Online: https://journals.sagepub.com/doi/10.1177/0284185120918807

About IAG, Image Analysis Group

Our goal is to accelerate novel drug development by using the right analytical tools and modern trial infrastructure. We take a broader view on the assets development and bring expertise in study design, execution, and commercialization. As needed, we deploy AI, Machine Learning, and smart image analysis methods to ensure the speed and cost-effectiveness of clinical programs. IAG’s team supports investors and biotech executive teams with deploying the right strategies for early efficacy assessments, objective response prediction and critical analysis of advanced treatment manifestations. Thus, lowering the investment risks into advanced therapies while helping to accelerate study outcomes.

Reach out to our expert team to discuss your development programs: imaging.experts@ia-grp.com

News
Events